Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

September
08
2021

Sensus Healthcare to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

Boca Raton, Fla., Sept. 08, 2021 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced that Joe Sardano, chairman…

August
26
2021

SRT Effectively Addresses NMSC, Keloids

Superficial radiation therapy (SRT) greatly reduces keloid recurrence rates and, for keratinocytic skin cancers, provides short-term cure rates similar to those in previous SRT research and of surgical options including Mohs surgery, Brian Berman, MD,…

August
25
2021

Avoid Basal Cell Carcinoma Removal Scar with SRT

If you’ve been diagnosed with Basal Cell Carcinoma (BCC), you are not alone. BCC is the most common form of skin cancer, with an estimated 3.6 million cases diagnosed every year in the U.S. alone….

August
18
2021

Music City Scale

Join Sensus Healthcare at Music City Scale at the Grand Hyatt!

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy